

Call: 226-806-5690 Fax: 519-749-4356

## REFERRAL for ANTIVIRAL (Paxlovid® PO/ Remdesivir IV) therapy—Covid-19 Patients (Adult)

Primary Care Provide			Information				
irst Name	Last Name	First Name Last Name					
		Address			1		
			AFFIX P	ATIENT INFO	RMATION ST	ICKER	
ontact no:							
		Contact n	0:				
xclusions: (if any on	e criteria is met, patient doe	s NOT qua	lify for therapy.	Do not refer for	assessment)		
Greater than 7 da			ake COVID the		Covid Test – Ne	gative	
	, , , , , , , , , , , , , , , , , , , ,	3		17		<b>J</b>	
clusions: must me	et criteria for "Higher risk	of severe	disease" to p	roceed with tre	eatment		
405			Normalian of Ma	i D			
AGE (years)	0 doses	Number of Vaccine Doses 1 or 2 doses			3 doses		
18-59	Higher risk if ≥1 risk				Standard risk		
	•						
60-69	Higher :	risk		Standard risk			
≥70	Higher ricks not expected to	n mount or	Higher	r risk ne response to COVID-19 vaccination or SARS-CoV-			
nmunocompromised- of any age	nigher risk: not expected to			ie response to CC lying immune stat		UII UI SAKS-COV-	
Pregnancy	Higher risk		ard risk	,	Standard risk		
ate of positive COV	ID test://	_ Te	st: 🗆 RAT 🗆	PCR ID NO	W □ Pending	□ Not done	
-1		. (		0) /	1		
ate of symptom on:	set (must be ≤ 7 days, day	or symptor	n onset is Day	0):/	_/		
dicate:	nated (no. of doses)	☐ Ur	vaccinated	☐ Immuno	compromised	Pregnant	
nmunocompromise			Risk Fact				
	id tumors/malignancies ancies without active treatm	1		ity (BMI ≥ 30)			
Solid organ or ste	nent Diabetes Heart disease, hypertension, CHF						
CAR T-cell thera	Cystic Fibrosis or other chronic respiratory disease						
Anti-CD 20 agent	OR Cerebral palsy						
Alkylating agents	Intellectual disability of any severity						
Advanced or untreated HIV			Sickle cell disease				
	ary immunodeficiency		☐ Mod/Severe renal disease (eGFR < 60)				
	s or other biologic agents	☐ Mod/Severe liver disease (Child Pugh score B or C					
Taking chronic oral corticosteroid (greater than 20 mg/d prednisone equivalent for > 2 weeks)							
20 mg/a preanisc	one equivalent for > 2 weeks	S)					
rug Interaction Ass	essment:						
	review eligibility, assess dru	ıg interacti	ons and confin	m dosing prior to	releasing any	medication.	
ailure to provide th	is information will delay ti	imely asse	essment for th	erapy.	,		
Attach current me	dication list including any he	erbal produ	ucts / nutraceut	ticals (include dr	ug, dose, and fi	requency)	
l Dotiont's barrer	ormooy/obana ny						
j Patient's nome pn ab Assessment	armacy/phone number:						
	irment: YES NO	UNKNO	A/NI				
<ul><li>Existing liver impa</li><li>Existing renal impa</li></ul>		UNKNO					
	to liver or renal impairment		VIN				
	st recent renal function (SC		), bilirubin. albu	ımin, and INR re	sults		
Ascites (circle			e/difficult to cor				
	,	rade 1-2	Grade 3-4				
referring the patient a	and if medication is prescrib	ed, the refe	erring provider	assumes respon	sibility for all fol	low-up based or	
	ns from the Regional Covid			-	-	•	
erring Physician (Pri	nt Name) Refe	rring Phys	ician Signature	<u> </u>	Contact no:	Date	